APOE

There are 3,893 papers on APOE in aging research: 137 trials and 2,856 observational studies in people, 489 in animals, 18 in cells, 275 reviews. The newest story, Nov 18, 2026: “Mice modeling late-onset Alzheimer’s show memory problems”.

Gene

3,893 papers study it1,581 findings

HGNCMGINCBI GeneTaxon

103 new papers in 30 daysSee all 3,893 papers on APOE

At a glance

APOE is linked with poorer cognition and higher dementia risk in humans, associations reported again by independent labs; independent labs also report senescence induction in human cells. Some cognitive results point the other way. Funders include the National Institute on Aging; some authors work at companies, and some papers declare company ties.

1,581 findings in 1,146 papers from 1993 to 2026, 161 of them since April 2026

Independent labs found the same change in cells, mice and people. 304 independent labs in 53 countries.

“The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001)”
Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trialAlzheimer's & dementia : the journal of the Alzheimer's Association2024doi:10.1002/alz.13843

127 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 304 independent labs in 53 countries
  • 127 findings against
  • Funders: National Institute on Aging and others
  • 207 of 1,473 findings with company ties
  • Human trial137
  • Humans2,856
  • Animals484
  • Model organisms5
  • Cells18
  • In silico84

Interventions

2

Recombinant human APOE2

downin mouse cells1

1 study
  1. Recombinant human APOE2 decreases APOE in ApoE4-knockin mouse primary neurons.

    “decreases in endogenous ApoE4 protein levels”

    Cellsin ApoE4-knockin mouse primary neurons

    Protein improved brain metabolism and memory in aging mice

    bioRxiv : the preprint server for biologyPreprint

More on Recombinant human APOE2

Box a of HMGB1 plasmid

upin cynomolgus monkeys1

1 study
  1. Box a of HMGB1 plasmid improves APOE in cynomolgus monkeys (perimenopausal monkeys).

    “Notably, the expression levels of key proteins, such as apolipoprotein E (APOE) and sex hormone-binding globulin (SHBG), showed a reversal effect”

    Animalsperimenopausal monkeysplasmidplasmafemales

    Box A of HMGB1 plasmid reverses the age-related changes in the plasma proteomic profile of perimenopausal monkeys

    Scientific reports

More on Box a of HMGB1 plasmid

Effects

252

Cognitive function

downin humans18no changein humans6downin mice4upin humans2+1

31 studies
  1. APOE was not clearly linked with cognitive function in humans (Cognitively intact adults; APOE-ε4 carriers versus noncarriers).

    “standard cognitive measures did not demonstrate significant APOE-ε4-related differences in this cohort.”

    HumansCognitively intact adults; APOE-ε4 carriers versus noncarriersn = 42

    Exploratory associations between APOE-ε4 carrier status and facial neuromuscular activity in cognitively intact adults: a cross-sectional surface electromyography study

    Frontiers in neurology

  2. APOE is linked with worse cognitive function in participants of European ancestry (Mdiff -0.4 to -0.9, ps < .001).

    “Homozygote carriers scored lower than heterozygote carriers (Mdiff: first = -0.5; lowest = -0.9), who scored lower than non-carriers (Mdiff: first = -0.4; lowest = -0.6).”

    Humansin participants of European ancestry

    Curation of Mini Mental State Examination (MMSE) Scores in the VA Million Veteran Program (MVP): Applications for Cognitive Aging Research

    medRxiv : the preprint server for health sciencesPreprint

  3. APOE is linked with worse cognitive function in humans with higher concentrations of pTau217 (greater decline).

    “APOE ε4 allele carriers with higher concentrations of pTau217 showed a greater decline in longitudinal task performance”

    Humanswith higher concentrations of pTau217

    Validation of longitudinal change in proper name recall with pTau217 as a marker of early cognitive decline in cognitively unimpaired adults at risk for Alzheimer's disease dementia

    Journal of Alzheimer's disease : JAD

  4. APOE is linked with worse cognitive function in humans (compared with noncarriers) (estimate -0.005, SE 0.001, P = .001).

    “APOE ε4 carriage was associated with a significantly steeper quadratic age-associated decline in MMSE scores compared with noncarriers (estimate, -0.005; SE, 0.001; P = .001).”

    Humanscompared with noncarriersmean 6.3 yearsn = 4,392

    APOE ε4 and Accelerated Cognitive Decline Among Cognitively Healthy Middle-Aged and Older Adults

    JAMA network open

  5. APOE is linked with worse cognitive function in humans under increasing recognition-task demand.

    “and in older APOE4 carriers compared to older non-carriers”

    Humansunder increasing recognition-task demand

    Episodic memory retrieval with increasing task demand: Associations with age, APOE4 genotype, and Alzheimer's disease pathology

    medRxivPreprint

  6. APOE is linked with worse cognitive function in humans (multiple TBIs) (-17.22 points compared with -7.21, P < .001).

    “female APOE ε4 allele carriers with multiple TBIs exhibited worse outcomes on global cognition (P < .001; eg, ε4+/TBI2+ estimated marginal means [EMMs] from baseline to year 10 = -17.22 points”

    Humansmultiple TBIsfemales

    Sex differences in genetic modifiers of traumatic brain injury and late-life cognitive decline: the Cache County study

    The journals of gerontology. Series A, Biological sciences and medical sciences

  7. APOE was not clearly linked with cognitive function in humans (cognitively healthy or MCI, excluding dementia and ε4 homozygotes) (β = -0.36, p = .430).

    “APOE status was not a significant predictor for performance on memory ( β = ‐0.36, p = .430) or attention ( β = 0.52, p = .265) measures.”

    Humanscognitively healthy or MCI, excluding dementia and ε4 homozygotesn = 190

    Does Neighborhood Disadvantage Moderate the Relationship between Apolipoprotein E Status and Cognitive Functioning?

    AAIC 2025 abstract

  8. APOE was not clearly linked with cognitive function in humans (subjective cognitive decline) (p = 0.217).

    “Findings from the linear mixed model indicated that ε4+ was not a significant predictor of cognitive decline in SCD patients over one year, p = 0.217.”

    Humanssubjective cognitive decline

    Impact of APOE ε4 on Cognitive Progression in Individuals with Subjective Cognitive Decline: Preliminary Data from a Brazilian Cohort

    AAIC 2025 abstract

  9. APOE is linked with worse cognitive function in humans (cognitively healthy) (F(1,48) = 4.51, p = 0.039).

    “ANCOVA showed that APOE status significantly influenced cognitive performance [F(1,48) = 4.51; p = 0.039]”

    Humanscognitively healthyn = 83

    The Association Between Physical Activity, APOE Genotype, and Cognitive Performance in Cognitively Healthy Older Adults: Findings from a Brazilian Cohort

    AAIC 2025 abstract

  10. APOE is linked with worse cognitive function in humans (β = -0.053, p = 0.006).

    “their MMSE scores were significantly lower (total population: β=‐0.053, p = 0.006”

    Humansn = 1,692

    Effects of Apolipoprotein E Genotype and Education on Cognitive Function

    AAIC 2025 abstract

All 32

Lifespan

no changein humans2no changein flies1downin silico1

4 studies
  1. APOE was not clearly linked with lifespan in humans.

    “ApoE genotypes did not differ significantly between older and younger groups.”

    Humans

    Immunogenetics of longevity and its association with human endogenous retrovirus K

    Frontiers in aging

  2. APOE showed no clear effect on lifespan in flies (standard housing conditions).

    “The lifespan of APOE3 and APOE4 flies do not differ under standard housing conditions”

    Model organismsstandard housing conditions

    Progressive behavioral and cognitive decline in Drosophila harboring AD- associated APOE4 variants

    bioRxiv : the preprint server for biologyPreprint

  3. APOE shortens lifespan in silico.

    “rs7412-C variant showing a strong association with reduced lifespan”

    In silico

    Bioinformatic and genomic analysis identifies C allele of APOE rs7412 as the most prominent variant limiting extreme human longevity

    Scientific reports

  4. APOE showed no clear effect on lifespan in humans (APOE loss-of-function mutations).

    “without compromising longevity.”

    ReviewAPOE loss-of-function mutations

    APOE loss of function: A genetic shield against Alzheimer's disease

    Neuron

Cognitive decline

upin humans3upin mice1

4 studies
  1. APOE is linked with higher cognitive decline in MC-1.

    “greater impact of tau pathology on neuronal chromatin architecture, white matter loss, and APOEε4-related cognitive decline in MC-1.”

    Humansin MC-1

    Multi-region brain transcriptomes uncover two subtypes of aging individuals with differences in Alzheimer risk and the impact of APOEε4

    iScience

  2. APOE is linked with higher cognitive decline in humans with elevated t-tau, NfL, or GFAP.

    “higher neurodegeneration (t‐tau), axonal injuries (NfL), and reactive astrocytes and neuroinflammation (GFAP) accelerated cognitive decline in genetically susceptible APOE4 carriers”

    Humanswith elevated t-tau, NfL, or GFAPn = 1,038

    Compounding Effects of APOE4 and Blood Neurodegenerative Biomarkers on Cognitive Decline in Community‐dwelling Older Adults

    AAIC 2025 abstract

  3. APOE is linked with higher cognitive decline in humans.

    “and the average rate of decline was faster than among APOE ε4 noncarriers.”

    Humans

    Approaches to Timescale Choice in Cognitive Aging Research and Potential Implications for Estimated Exposure Effects: Coordinated Analyses in 10 Cohorts of Older Adults

    Epidemiology (Cambridge, Mass.)

  4. APOE increases cognitive decline in male versus female aged mice.

    “Male aged apoE4-TR mice are more vulnerable to cognitive decline than females.”

    Animalsin male versus female aged micemales

    Sex differences in cognition, anxiety-phenotype and therapeutic effect of metformin in the aged apoE-TR mice

    Biology of sex differences

p-Tau217

no changein humans2upin humans2+57% higher

4 studies
  1. APOE was not clearly linked with p-Tau217 in humans (cognitively unimpaired, amyloid-beta-negative).

    “No significant associations were found between p-tau217 and APOE genotype.”

    Humanscognitively unimpaired, amyloid-beta-negativeplasma

    Marker linked to age in cognitively intact, amyloid-negative adults

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. APOE is linked with higher p-Tau217 in humans (sedentary lifestyle, hypertension, and hypercholesterolemia) (57% higher).

    “Plasma p-tau217 was 57% higher in subjects with at least one APOE ε4 allele”

    Humanssedentary lifestyle, hypertension, and hypercholesterolemiaplasman = 400

    Plasma p-tau217 and APOE genotype: Prodromal Alzheimer's disease staging

    Alzheimer's & dementia (Amsterdam, Netherlands)

  3. APOE was not clearly linked with p-Tau217 in adults with Down syndrome.

    “Individuals that are carriers of the APOE ε4 allele present with similar baseline amyloid and pTau217 values ( p = .591 & p = .455 respectively).”

    Humansin adults with Down syndrome

    APOE ε4 Does not increase rate of amyloid accumulation or tau phosphorylation in adults with Down Syndrome

    AAIC 2025 abstract

  4. APOE is linked with higher p-Tau217 in humans (subjective cognitive decline).

    “Compared to non‐ APOE ε4 participants, APOE ε4 carriers showed higher levels of plasma p ‐tau217.”

    Humanssubjective cognitive declineplasman = 148

    Association of blood ptau‐217 with Memory Performance and APOE ε4 in Individuals with Subjective Cognitive Decline: insights from the BRASCODE Cohort

    AAIC 2025 abstract

More on p-Tau217

Total brain volume

no changein humans1upin mice1downin mice1

3 studies
  1. APOE was not clearly linked with total brain volume in humans (longitudinally).

    “No APOE genotype or sex main effects were observed for TBV-Ratio.”

    Humanslongitudinallybrain4.7 yearsn = 5,774

    Two APOE ε4 copies linked to faster hippocampal shrinkage

    Neuroradiology

  2. APOE increases total brain volume in mice (APOE-ε4 carriers in humanized knock-in mice).

    “was greater in APOE-ε4 carriers”

    AnimalsAPOE-ε4 carriers in humanized knock-in micebrain

    Humanized APOE mouse brain volume increases over age irrespective of sex and APOE genotype: implications for translational validity to the human

    Frontiers in neuroscience

  3. APOE decreases total brain volume in hAPP background; APOE4/4 compared with other hAPOE genotypes.

    “Across hAPP models, hAPOE4/4 exhibited the greatest brain-wide reductions, which was mitigated by a single hAPOE3 allele.”

    Animalsin hAPP background; APOE4/4 compared with other hAPOE genotypesbrain

    Addition of humanized APP to humanized APOE mouse model reduces brain size and increases the ratio of cortical representation

    bioRxiv : the preprint server for biologyPreprint

More on Total brain volume

NfL

downin humans1no changein humans1upin humans1

3 studies
  1. APOE is linked with lower NfL in PSEN1 E280A carriers (f2=0.133).

    “and NfL (f2=0.133) among PSEN1 E280A carriers”

    Humansin PSEN1 E280A carriers

    Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers

    Research SquarePreprint

  2. APOE was not clearly linked with NfL in Hispanics/Latinos.

    “but not with NfL”

    Humansin Hispanics/Latinos

    APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  3. APOE is linked with higher NfL in humans (cognitively unimpaired APOE ε4 homozygotes vs. non-carriers) (21.4 pg/ml vs. 15.5 pg/ml, p = 0.013).

    “Serum NfL concentration was increased in APOE ε4 homozygotes compared with non-carriers (mean 21.4 pg/ml (SD 9.5) vs. 15.5 pg/ml (3.8), p = 0.013)”

    Humanscognitively unimpaired APOE ε4 homozygotes vs. non-carriersserum

    Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly

    Alzheimer's research & therapy

More on NfL

Cerebral blood flow

no changein humans1upin humans1downin mice1

3 studies
  1. APOE was not clearly linked with cerebral blood flow in humans (cognitively unimpaired Veterans at baseline) (MF p: 0.16-0.92; PI p: 0.055-0.98).

    “APOE ε4 carriers ( n = 28) and non‐carriers ( n = 89) had similar baseline blood flow (MF p ‐value range: 0.16‐0.92; PI p ‐value range: 0.055‐0.98).”

    Humanscognitively unimpaired Veterans at baseline

    Effects of Icosapent Ethyl, APOE Genotype and CSF Biomarkers on 4D Flow MRI Metrics of Vascular Health in Cognitively Unimpaired Veterans

    AAIC 2025 abstract

  2. APOE is linked with higher cerebral blood flow in humans (sedentary, amyloid-β positive older adults).

    “higher android fat percentage and APOE ε4 carrier status were most strongly associated with higher blood flow among female participants.”

    Humanssedentary, amyloid-β positive older adultsbrainfemalesn = 112

    APOE4 and Chronic Health Risk Factors are Associated with Sex-Specific Preclinical Alzheimer's Disease Neuroimaging Biomarkers

    medRxiv : the preprint server for health sciencesPreprint

  3. APOE impairs cerebral blood flow in mice (humanized transgenic APOE4 knock-in mice compared to APOE3).

    “Findings demonstrate genotype‐dependent and age‐related differences in vascular dynamics such as cerebral blood flow and BBB permeability.”

    Animalshumanized transgenic APOE4 knock-in mice compared to APOE3brain

    Unravelling the role of APOE4 in vascular dysfunction and cognitive impairment

    AAIC 2025 abstract

Inflammation

upin humans1upin mice1

2 studies
  1. APOE is linked with higher inflammation in humans (independent of AD diagnosis).

    “We identify a conserved, allele dose-dependent pro-inflammatory immune protein signature across peripheral and central tissues independent of AD diagnosis.”

    Humansindependent of AD diagnosis

    Cross-tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. APOE increases inflammation in mice (ApoE4/4 knock-in mice).

    “Here we show that ApoE4 mice develop severe hepatic steatosis, neuroinflammation and lipid raft rigidification”

    AnimalsApoE4/4 knock-in micebrainfemales

    Dietary fat rebalanced brain membrane fats in mice

    Molecular biomedicine

More on Inflammation

Type 2 diabetes

no changein humans2OR 1.13

2 studies
  1. APOE was not clearly linked with type 2 diabetes in humans (ps ≥ .09).

    “T2DM incidence did not differ significantly by APOE status (ps ≥ .09).”

    Humansfemalesn = 6,795

    Relationships Between APOE, Type 2 Diabetes, and Cardiovascular Disease in Postmenopausal Women

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. APOE showed no clear effect on type 2 diabetes in humans (APOE E4/E4 versus other genotypes; recessive genetic model) (OR 1.13, 95% CI 0.73–1.75).

    “No significant effect was observed in the recessive (E4/E4 vs. others; OR = 1.13, 95% CI: 0.73-1.75)”

    ReviewAPOE E4/E4 versus other genotypes; recessive genetic model

    Genetic Variation of ApoE Gene in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Case-Control Studies

    International journal of preventive medicine

More on Type 2 diabetes

GFAP

downin humans1upin humans1

2 studies
  1. APOE is linked with lower GFAP in PSEN1 E280A carriers (f2=0.247).

    “APOE3 Ch heterozygosity was associated with significantly attenuated age-related increases in GFAP (f2=0.247)”

    Humansin PSEN1 E280A carriers

    Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers

    Research SquarePreprint

  2. APOE is linked with higher GFAP in humans (APOE ε4 carriage and slow gait in mild cognitive impairment) (F1, 312 = 7.17, p = 0.008).

    “individuals with APOE ε4 and SG had significantly higher plasma GFAP levels.”

    HumansAPOE ε4 carriage and slow gait in mild cognitive impairmentplasma

    Elevated plasma GFAP levels in MCI link APOE ε4 allele with impaired gait speed

    GeroScience

More on GFAP

DTI-ALPS index

downin humans1

1 study
  1. APOE decreases DTI-ALPS index in humans (baseline) (Cohen's d = 0.61).

    “Specifically, APOE ε4 carriers (M = −0.0199, SD = 0.0436) exhibited significantly lower baseline bilateral DTI-ALPS index compared to non-carriers (M = 0.0070, SD = 0.0447).”

    Human trialbaselinebrainapproximately 6 monthsn = 36

    The glymphatic system as a therapeutic target: TMS-induced modulation in older adults

    Frontiers in aging neuroscience

  2. APOE decreases DTI-ALPS index in older adults with mild cognitive impairment (p < 0.05, Cohen's d = 0.610).

    “Specifically, ε4 carriers exhibited a lower baseline DTI-ALPS index (p < 0.05, Cohen's d = 0.610)”

    Human trialin older adults with mild cognitive impairmentbrain

    The glymphatic system as a therapeutic target: TMS-induced modulation in older adults

    Frontiers in aging neuroscience

More on DTI-ALPS index

Attention, executive function, mental flexibility, processing speed, verbal memory, and working memory response to aerobic exercise

no changein humans1

1 study
  1. APOE showed no clear effect on attention, executive function, mental flexibility, processing speed, verbal memory, and working memory response to aerobic exercise in humans (APOE4 carriage moderation analysis in postmenopausal women with breast cancer).

    “There were no other significant findings for attention, executive function, mental flexibility, processing speed, verbal memory, or working memory.”

    Human trialAPOE4 carriage moderation analysis in postmenopausal women with breast cancer6 monthsfemalesn = 116

    APOE Genotype-specific Cognitive Response to Aerobic Exercise in Postmenopausal Women with Breast Cancer

    Biological research for nursing

Global cognition

downin humans1

1 study
  1. APOE impairs global cognition in humans (mild cognitive impairment, multidomain intervention) (mean difference = -2.08, 95% CI: -4.18 to 0.11, d = -0.56).

    “APOE4‐positive participants showed attenuated global cognitive improvements from multidomain interventions compared to APOE4‐negative participants (mean difference = ‐2.08, 95% CI: ‐4.18 to 0.11; p = 0.052; d = ‐0.56).”

    Human trialmild cognitive impairment, multidomain intervention6 monthsn = 67

    Does APOE4 genotype moderate the effects of multidomain exercise interventions in older individuals living with mild cognitive impairment?

    AAIC 2025 abstract

Dual-task functional power training

no changein humans1

1 study
  1. APOE showed no clear effect on dual-task functional power training in humans.

    “No significant BDNF or APOE genotype interactions were detected for any biomarker changes.”

    Human trial6 monthsn = 300

    Effects of a 6-month dual-task, power-based exercise program on cognitive function, neurological and inflammatory markers in older adults: secondary analysis of a cluster randomised controlled trial

    GeroScience

More on Dual-task functional power training

Physical activity

no changein humans1

1 study
  1. APOE showed no clear effect on physical activity in humans.

    “There was no significant difference in APOE ε4 carriers versus non‐carriers in this model.”

    Human trial12‐week intervention period and 3‐week follow‐up periodn = 94

    Effect of gamification with a support partner to increase physical activity in older adults at risk for Alzheimer's disease: The STEP 4Life randomized clinical trial

    Alzheimer's & dementia : the journal of the Alzheimer's Association

All 252

Upstream

4

mTOR signaling

mediatesin human cells1

1 study
  1. mTOR signaling mediates APOE in human cells during mitochondrial dysfunction.

    “Protein stress initiates APOE expression and facilitates mitochondrial dysfunction's impact on APOE by engaging the mTOR pathway.”

    Cellsduring mitochondrial dysfunction

    An aging hallmark, Alzheimer's disease, and APOE nexus

    Journal of Alzheimer's disease : JAD

More on mTOR signaling

Protein stress

upin human cells1

1 study
  1. protein stress increases APOE in human cells (protein stress manipulated in cultured cells).

    “Increasing protein stress elevated and decreasing protein stress lowered APOE expression.”

    Cellsprotein stress manipulated in cultured cells

    An aging hallmark, Alzheimer's disease, and APOE nexus

    Journal of Alzheimer's disease : JAD

Microglia

upin reviews1

1 study
  1. Microglia increases APOE with aging, injury and AD-related pathology.

    “microglia, oligodendrocyte-lineage cells, vascular-associated populations, and border-interface macrophages exhibit context-dependent induction that is strongly influenced by aging, injury, and AD-related pathology”

    Reviewwith aging, injury and AD-related pathologycentral nervous system

    ApoE expression across the CNS: Who, What, Where, When, and How (much)?

    Molecular neurodegeneration advances

Age-related hearing loss

upin mice1

1 study
  1. Age-related hearing loss increases APOE in mice (age-related hearing loss).

    “Validation via qRT-PCR, Western blot, and immunofluorescence demonstrated that both ApoE and Spp1 were highly expressed in the cochlea and auditory cortex of the ARHL mice”

    Animalsage-related hearing losscochlea

    Expression of ApoE and Spp1 in the cochlea and auditory cortex of age-related hearing loss mice

    Brazilian journal of otorhinolaryngology

More on Age-related hearing loss

Associations

303

Alzheimer's disease

upin humans29upin silico6mixedin humans2downin humans1+1HR 0.87–7.79

38 studies
  1. APOE predicts Alzheimer's disease in MCI individuals (HR 1.83 per allele (p=0.008)).

    “APOE4 keeps predicting conversion on its own, at an HR of 1.83 per allele (p=0.008).”

    Humansin MCI individuals

    A leakage-controlled multi-compartment benchmark of fluid biomarkers for predicting mild cognitive impairment to Alzheimer's disease conversion: plasma, CSF, and high-plex omics in a single cohort

    Research squarePreprint

  2. APOE is linked with a higher risk of Alzheimer's disease in humans (APOE ε4 carriers vs non-carriers) (HR = 7.79 [6.18-9.81]).

    “APOE ε4 carriers had higher AD risk than non-carriers (HR = 7.79 [6.18-9.81])”

    HumansAPOE ε4 carriers vs non-carriers12.8 yearsn = 18,212

    Blood protein links to Alzheimer’s differed by genetic risk

    Research squarePreprint

  3. APOE is linked with a higher risk of Alzheimer's disease in humans (APOE ε4 genotype) (p < 0.05).

    “Multivariate logistic regression identified the apolipoprotein E epsilon 4 allele (APOE ε4) genotype, cerebrospinal fluid (CSF) p-tau181/amyloid-beta 42 (Aβ42) ratio, and diabetes as independent risk factors for AD (p < 0.05)”

    HumansAPOE ε4 genotypen = 350

    AI-Enabled Modeling for Alzheimer's Disease Risk Prediction and Validation

    Revista de neurologia

  4. APOE predicts Alzheimer's disease in individuals with mild cognitive impairment (OR 1.82, p = 0.021).

    “and APOE ε4 carriage (OR 1.82, p = 0.021).”

    Humansin individuals with mild cognitive impairment

    Integrated amyloid, neurodegeneration, and vascular biomarkers estimate the risk of dementia progression in mild cognitive impairment

    Journal of Alzheimer's disease : JAD

  5. APOE is linked with a higher risk of Alzheimer's disease in APOE ε4 carriers.

    “These effects were amplified by APOE ε4 and attenuated by ε3, while ε2 showed no influence.”

    Humansin APOE ε4 carriersfemales

    Age at natural menopause, reproductive lifespan and Alzheimer's disease in females: is APOE ε4 the missing link?

    Frontiers in genetics

  6. APOE is linked with a higher risk of Alzheimer's disease in humans (p<10−6).

    “Both approaches identified genome-wide significant associations (p<10−6) within the APOE locus, consistent with established Alzheimer’s disease risk factors.”

    Humans

    Identifying single-nucleotide polymorphisms (SNPs) intersecting Alzheimer’s disease pathology and end-of-life traits using genomic informational field theory (GIFT)

    medRxivPreprint

  7. APOE is linked with a higher risk of Alzheimer's disease in humans (compared to non-carriers) (HR = 4.33, 95% CI: 4.01-4.68).

    “and over a fourfold increased risk of AD (HR = 4.33, 95% CI: 4.01-4.68).”

    Humanscompared to non-carriersmedian follow-up: 13.8 yearsn = 345,785

    Genetic versus Modifiable Risk: Predicting Dementia, Cognition, and Brain Structure in the UK Biobank

    medRxivPreprint

  8. APOE is associated with Alzheimer's disease in humans (APOE-ε4 allele dosage) (11.1 vs 15.9 vs 23.7 per 1,000 person-years).

    “the incidence rates (95% CI) of AD/ADRD per 1,000 person-years were 11.1 (8.8–13.9) in individuals without APOE-ε4, 15.9 (11.7–21.7) in those with one copy, and 23.7 (8.9–63.0) in those with two copies of APOE-ε4.”

    HumansAPOE-ε4 allele dosage30 yearsn = 469

    Predictive Value of the Proteomic Aging Clock and APOE Genotype for Incident Alzheimer’s Disease Risk

    GSA 2025 abstract

  9. APOE is associated with Alzheimer's disease in humans (APOE ε4 allele in a Latino population).

    “The APOE ε4 allele was significantly associated with AD.”

    HumansAPOE ε4 allele in a Latino population

    Enhanced Cognitive Function in the Latino Population: The Familism and Lifestyle

    Preprints.orgPreprint

  10. APOE is linked with a higher risk of Alzheimer's disease in patients who have experienced TIAs (45% vs 25% (p < 0.05)).

    “APOE4 carriers were at much higher risk of developing AD, having an incidence of 45% as opposed to 25% in non‐carriers (p < 0.05).”

    Humansin patients who have experienced TIAsn = 300

    Impact of APOE4 Genotype and Lifestyle Factors on Alzheimer’s Disease Risk in Patients with Transient Ischemic Attacks: A Comparative Cohort Study

    AAIC 2025 abstract

All 39

More on Alzheimer's disease

Dementia

upin humans29mixedin humans2downin humans2+80% higher riskHR 0.67–4.2

31 studies
  1. APOE is associated with dementia in humans (Total sample and people without HIV; rs429358 and rs769449) (rs429358: P = 8.8×10 –18; rs769449: P = 1.48 × 10 –12).

    “Across total sample and people without HIV, three genome-wide significant single nucleotide polymorphisms (SNPs) were identified: rs429358 (gene: APOE , P = 8.8×10 –18 )”

    HumansTotal sample and people without HIV; rs429358 and rs769449

    Genetic links to dementia may differ with HIV status

    AIDS (London, England)

  2. APOE is associated with dementia in humans (Association differs by sex).

    “The association between APOE {varepsilon}4 carrier status and dementia differed by sex (interaction p = 0.027).”

    HumansAssociation differs by sexn = 43,759

    Dementia blood predictors vary by sex and genetic risk

    medRxivPreprint

  3. APOE is linked with a higher risk of dementia in humans (APOE4 carriers, allele dosage-dependent).

    “We revealed graded, allele dosage‐dependent risk elevations for ACD, AD and VaD among APOE4 carriers”

    HumansAPOE4 carriers, allele dosage-dependent

    Brain and blood markers link APOE4 to dementia risk

    Research SquarePreprint

  4. APOE is linked with a higher risk of dementia in Europeans.

    “and larger dementia risk for Europeans.”

    Humansin Europeans

    APOE disease risks and proteomic links vary by ancestry

    medRxivPreprint

  5. APOE is linked with a higher risk of dementia in humans following epilepsy onset, one copy of APOE ε4 (approximately 80% higher risk).

    “carrying one copy of the APOE ε4 allele having an approximately 80% higher risk of dementia after epilepsy”

    Humansfollowing epilepsy onset, one copy of APOE ε4

    APOE ε4 associates with epilepsy, dementia, and higher mortality

    Human genetics

  6. APOE is linked with a higher risk of dementia in humans (poor profile with APOE ε4 carriers vs favorable-profile non-carriers) (HR 2.32, 95% CI 1.73-3.12).

    “Relative to favorable-profile APOE ε4 non-carriers, dementia risk was highest among participants with a poor profile who were APOE ε4 carriers (HR 2.32, 95% CI 1.73-3.12).”

    Humanspoor profile with APOE ε4 carriers vs favorable-profile non-carriers31-year58% femalesn = 14,333

    Dementia polygenic score links to dementia, disability, and death

    medRxiv : the preprint server for health sciencesPreprint

  7. APOE is associated with dementia in humans (exploratory analyses).

    “In exploratory analyses, apolipoprotein E ε4 genotype, thoracic aortic calcium, and plasma neurofilament light chain were associated with incident dementia”

    Humansexploratory analysesmedian of 4.7 yearsn = 730

    Incidence of dementia and mild cognitive impairment in two Indigenous Bolivian cohorts

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  8. APOE is associated with dementia in humans (multiplicative interaction) (P for interaction = 0.032).

    “Additionally, a significant multiplicative interaction was observed between APOE-ε4 status and the TyG index (P for interaction = 0.032).”

    Humansmultiplicative interaction

    Triglyceride-Glucose Indices, Genetic Susceptibility, and Incident Dementia Risk Across Early CKM Syndrome Stages: A UK Biobank Prospective Cohort Study

    Research SquarePreprint

  9. APOE is associated with dementia in humans.

    “APOE ε4 carriage was most frequent among participants with dementia”

    Humansn = 292

    An Integrated Model Based on Gut Microbiota and APOE Genotype for Predicting Dementia Risk

    Brain sciences

  10. APOE is linked with a higher risk of dementia in humans (versus neutral APOE ε3ε3) (advanced dementia risk by 5.58 years (q<0.001)).

    “versus neutral APOE ε3ε3, ε4 presence advanced dementia risk by 5.58 years”

    Humansversus neutral APOE ε3ε313.6 yearsn = 224,516

    Associations of lifestyle factors and genetic risk with risk and rate advancement periods of dementia

    Preprint

All 33

More on Dementia

Cognitive function

downin humans12mixedin humans3upin humans1

16 studies
  1. APOE is associated with cognitive function in humans (APOE ε4 carriers versus non-carriers).

    “APOE ε4 was associated with lower FAMS and higher TEA, but results were not statistically significant.”

    HumansAPOE ε4 carriers versus non-carriersn = 422

    Exploring the role of depression in the association between APOE ε4 and cognitive function: Evidence from the Brain Health Registry

    Journal of psychiatric research

  2. APOE is associated with cognitive function in humans (nonmetastatic breast cancer, exposed to endocrine therapy, at 5 years).

    “At 5 years, however, women with breast cancer exposed to endocrine therapy and APOE4 carriers in particular exhibited lower learning and memory scores than other groups (P < .05).”

    Humansnonmetastatic breast cancer, exposed to endocrine therapy, at 5 years5-year follow-upfemales

    Interaction of endocrine therapy for breast cancer with APOE4 status on cognition over 5-year follow-up

    JNCI cancer spectrum

  3. APOE is associated with cognitive function in humans (APOE e4 carrier vs non-carrier).

    “Both APOE carrier status and COX7A1 UTR hexanucleotide repeat number were found to result in a statistically significant difference in MoCA z‐score.”

    HumansAPOE e4 carrier vs non-carriern = 296

    The Influence of Variation in Hexanucleotide Repeat Number in the 5’ Untranslated Region of Cytochrome C Oxidase Subunit 7A1 on the Development of Cognitive Impairment

    AAIC 2025 abstract

  4. APOE is associated with cognitive function in individuals with low educational attainment and elevated pTau181 (p = 0.045).

    “within the low EA group, APOE ε4 carriers had poorer cognitive function than non‐carriers ( p = 0.045).”

    Humansin individuals with low educational attainment and elevated pTau181

    Educational attainment mitigates cognitive decline associated with elevated pTau181 and APOE ε4 in Puerto Ricans

    AAIC 2025 abstract

  5. APOE is associated with cognitive function in humans.

    “Pleiotropy GWAS identified GWS associations with APOE and 11 novel loci.”

    Humansn = 25,726

    Genome‐Wide Pleiotropy Analysis of Longitudinal Blood Pressure and Harmonized Cognitive Performance Measures

    AAIC 2025 abstract

  6. APOE is associated with cognitive function in humans.

    “APOE-rs429358(C) was negatively associated with global cognitive function across ancestry groups.”

    Humans

    Genetic association analyses of cognitive performance across multi-ancestry older adults: Application of Tobit models

    Journal of Alzheimer's disease : JAD

  7. APOE is associated with cognitive function in humans (fully adjusted model) (B = -0.25, 95% CI [-0.45; -0.04], p = 0.02).

    “APOE 4 allele status emerged as a significant predictor (B = - 0.25, 95% CI [ - 0.45; - 0.04]; p = 0.02)”

    Humansfully adjusted modelfemalesn = 165

    The proportion of plant-based food consumption during midlife and cognitive health in later life in Australian women: data from the Women's Healthy Ageing Project (WHAP)

    European journal of nutrition

  8. APOE is associated with cognitive function in humans (APOE ε4 carriage; adjusted for age, sex, and education).

    “APOE ε4, diabetes, hypertension, and tobacco dependence each independently predicted lower performance across all four cognitive domains (adjusted p < .001)”

    HumansAPOE ε4 carriage; adjusted for age, sex, and education62.0% femalesn = 3,833

    Population intervention models of racial ethnic disparities in cognitive outcomes from cardiometabolic risk factors - HABS-HD

    Alzheimer's research & therapy

  9. APOE is associated with cognitive function in humans.

    “The APOE ε4 allele, PGSAD, PGSCP, PGSEA, and PGSSCZ were associated with baseline MMSE but not MMSE decline.”

    Humansn = 27,343

    Education as a Modifier of Genetic Influence on Cognitive Ability in Older Adults

    Behavior genetics

  10. APOE is associated with cognitive function in humans among those with AF.

    “APOE E4 allele carriage was associated with greater decline among those with AF.”

    Humansamong those with AF

    Cognitive trajectories and incident atrial fibrillation in the ASPREE cohort

    medRxiv : the preprint server for health sciencesPreprint

All 16

Cognitive impairment

upin humans16HR 1.23

16 studies
  1. APOE is linked with a higher risk of cognitive impairment in humans (HR 1.23, 95% CI 1.08-1.40).

    “ApoE ε4 genotype carriers had a higher risk for cognitive impairment compared with non-carriers (HR=1.23, 95%CI: 1.08-1.40)”

    Humans

    Joint effects of heatwave exposure and apolipoprotein E genotype on risk for cognitive impairment in older adults

    Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

  2. APOE is associated with cognitive impairment in the fully adjusted model.

    “APOE copy number were associated with higher risk for CI”

    Humansin the fully adjusted model

    Twenty-Year Glycemia Trajectories and Risk for Cognitive Impairment (CI) in Adults with Prediabetes or Type 2 Diabetes (T2D) in the Diabetes Prevention Program Outcomes Study (DPPOS)

    ADA Scientific Sessions 2026 abstract

  3. APOE is associated with cognitive impairment in humans (χ2 = 4.81, P = 0.03).

    “carriers of the APOE ε4 allele (χ 2 = 4.81, P = 0.03)”

    Humansmean 6.8 yearsn = 109

    Elevated functional magnetic resonance imaging activity in cognitively normal participants predicts future dementia

    Brain communications

  4. APOE predicts cognitive impairment in humans.

    “Multivariate logistic regression identified TSH (odds ratio, OR = 1.19), FT3 (OR = 0.68), age, education and APOE ε4 carrier status as independent predictors of cognitive impairment (ROC AUC = 0.786).”

    Humansn = 420

    Correlation between thyroid hormone levels and cognitive dysfunction in older patients with subclinical hypothyroidism : A matched groups retrospective study

    Wiener klinische Wochenschrift

  5. APOE is linked with a higher risk of cognitive impairment in humans (intracranial atherosclerosis) (OR 1.86).

    “After adjustment, APOE ε4remained associated with cognitive impairment (odds ratio [OR] 1.86).”

    Humansintracranial atherosclerosisn = 409

    APOE4 and cognition in intracranial atherosclerosis: beyond Alzheimer's pathology

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  6. APOE is linked with a higher risk of cognitive impairment in HCV patients carrying the APOE ɛ4 allele (aHR 2.60, 95% CI 0.96-7.08, P = 0.06).

    “Additionally, HCV patients carrying the APOE ɛ4 allele had a marginally higher risk (aHR: 2.60, 95% CI: 0.96-7.08, P = 0.06).”

    Humansin HCV patients carrying the APOE ɛ4 allele

    Association between hepatitis C virus infection and cognitive decline in seniors: further evidence from Taiwan

    Geriatric nursing (New York, N.Y.)

  7. APOE predicts cognitive impairment in Panamanian older adults.

    “ApoEε4 status was a significant predictor of cognitive impairment.”

    Humansin Panamanian older adultsn = 725

    The influence of APOEε4 on cognition in Hispanics: The Panama Aging Research Initiative ‐ Health Disparities Study

    AAIC 2025 abstract

  8. APOE is linked with a higher risk of cognitive impairment in humans (OR = 1.509, p = 0.035).

    “APOEε4 carriers exhibited a significantly higher risk of cognitive impairments (total population: OR=1.509, p = 0.035”

    Humansn = 1,692

    Effects of Apolipoprotein E Genotype and Education on Cognitive Function

    AAIC 2025 abstract

  9. APOE is linked with a higher risk of cognitive impairment in humans (APOE ε4 allele compared to APOE ε3 carriers) (HR: 1.23, 95% CI: 1.01‐1.59).

    “carriers of the APOE ε4 allele (HR: 1.23, 95% CI: 1.01‐1.59) have a higher risk of transition from cognitively healthy to cognitive impairment”

    HumansAPOE ε4 allele compared to APOE ε3 carriers15 yearsn = 6,488

    Healthy lifestyle factors outweigh influence of APOE genetic risk on extending cognitively healthy life expectancy

    AAIC 2025 abstract

  10. APOE is associated with cognitive impairment in humans (carrying two ε4 alleles vs no ε4 alleles) (OR = 3.31 (95% CI: 1.15-9.91)).

    “Those carrying two ε4 alleles exhibited three times the odds of CI (OR = 3.31 (95% CI: 1.15-9.91), p = 0.026) compared to those with no ε4 alleles.”

    Humanscarrying two ε4 alleles vs no ε4 allelesn = 310

    Relationship Between Apolipoprotein E Genotypes, Unhealthy Weight Status, and Cognitive Impairment in Older Adults of Predominantly African Descent

    Diseases (Basel, Switzerland)

All 16

More on Cognitive impairment

Mild cognitive impairment

upin humans7OR 1.48–6.6

7 studies
  1. APOE is associated with mild cognitive impairment in humans (compared to SCD) (OR 1.48, 95% CI 1.23-1.76).

    “higher in MCI compared to SCD (OR = 1.48, 95% CI 1.23-1.76, p <0.0001)”

    Humanscompared to SCD

    APOE in subjective cognitive decline: a systematic review and meta-analysis

    Journal of neurology

  2. APOE is associated with mild cognitive impairment in humans (MCI with slow gait compared to SCD alone) (OR = 3.21, 95% CI: 1.41-7.31).

    “APOE ε4 carriage was specifically and more strongly linked to MCI-SG (OR = 3.21, 95% CI: 1.41-7.31) compared with the SCD-A group.”

    HumansMCI with slow gait compared to SCD aloneAPOE ε4 allele

    Dual decline in gait and cognition as a high-risk clinical phenotype: differential associations with cerebral amyloid-β deposition and the apolipoprotein E ε4 allele and implications for integrated assessment

    Frontiers in aging neuroscience

  3. APOE is associated with mild cognitive impairment in humans (71.4% vs 31.1%).

    “MCI participants are more likely to be APOE4 carriers (71.4% vs CN, 31.1%)”

    Humansn = 183

    Investigating Salivary Extracellular Vesicles as Biomarkers for Alzheimer's Disease: ExosomeAD Study Design and Baseline Characteristics

    AAIC 2025 abstract

  4. APOE is associated with mild cognitive impairment in humans (accounting for competing risks of death).

    “APOE4 carrier status and (on average) male sex were also associated with increased risk of MCI and dementia.”

    Humansaccounting for competing risks of death

    Absolute risk of cognitive impairment by AD amyloid stages

    AAIC 2025 abstract

  5. APOE is linked with a higher risk of mild cognitive impairment in humans (compared to normal cognition group) (OR 6.60, 95% CI 1.39–31.34).

    “and MCI (OR=6.60, CI95%=1.39‐31.34, p = 0.02), compared to the NC group”

    Humanscompared to normal cognition groupn = 84

    Association of the APOEε 4 allele in Mexican‐mestizo older adults with subjective cognitive decline and mild cognitive impairment

    AAIC 2025 abstract

  6. APOE is associated with mild cognitive impairment in humans (APOE4 carriers) (HR = 9.55, p = 0.005).

    “APOE4 carriers had a significantly increased risk before age 70 (HR = 9.55, p = 0.005).”

    HumansAPOE4 carriers

    Modeling the age-specific incidence of mild cognitive impairment incorporating the time-varying relationship of Alzheimer's disease biomarkers over 28 years

    Journal of Alzheimer's disease : JAD

  7. Mild cognitive impairment is associated with APOE in humans.

    “APOE ε4 carrier status was significantly elevated in LMCI patients”

    Humans

    Mapping Divergent Subfield-Specific Hippocampal Degeneration in Mild Cognitive Impairment Continuum: Volumetric, Cognitive, and Genetic Predictors of Accelerated Hippocampal Biological Aging

    CNS neuroscience & therapeutics

More on Mild cognitive impairment

Mortality

upin humans4downin humans2mixedin humans1+39% higher riskHR 0.88–1.16

6 studies
  1. APOE is linked with a higher risk of mortality in participants with epilepsy, carrying two copies of APOE ε4 (approximately 39% higher risk).

    “approximately 39% higher risk of death in those carrying two copies of the APOE ε4 allele”

    Humansin participants with epilepsy, carrying two copies of APOE ε4

    APOE ε4 associates with epilepsy, dementia, and higher mortality

    Human genetics

  2. APOE is associated with mortality in admixed Brazilian post-mortem cohort (BAS).

    “we observed an excess of the ε4 European haplotypes in the BAS, which is consistent with a mortality pressure allelic effect in the European LA context.”

    Humansin admixed Brazilian post-mortem cohort (BAS)

    Is APOE ε2 always a protective allele? Deviations in Hardy-Weinberg equilibrium in admixed Brazilian elderly individuals

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  3. APOE is linked with a lower risk of mortality in humans (APOE ε2 carriers compared to APOE ε3 carriers) (HR: 0.88, 95% CI: 0.78‐0.98).

    “APOE ε2 carriers (HR: 0.88, 95% CI: 0.78‐0.98) show a decreased risk of transition from cognitively healthy to death”

    HumansAPOE ε2 carriers compared to APOE ε3 carriers15 yearsn = 6,488

    Healthy lifestyle factors outweigh influence of APOE genetic risk on extending cognitively healthy life expectancy

    AAIC 2025 abstract

  4. APOE is linked with a higher risk of mortality in humans (ε4 allele; decedents with mixed AD neuropathology).

    “APOE ε4 decreased mortality risk in decedents without AD neuropathology and increased mortality in decedents with mixed AD neuropathology”

    Humansε4 allele; decedents with mixed AD neuropathology

    Subtypes of multiple-etiology dementias and the heterogeneous impact of APOE variants

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  5. APOE is linked with a lower risk of mortality in humans (ε4 allele; decedents without AD neuropathology).

    “APOE ε4 decreased mortality risk in decedents without AD neuropathology”

    Humansε4 allele; decedents without AD neuropathology

    Subtypes of multiple-etiology dementias and the heterogeneous impact of APOE variants

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  6. APOE is linked with a higher risk of mortality in humans (heterozygotes, compared with non-carriers) (HR 1.16 (95% CI 1.07-1.26)).

    “APOE4 carriers (3264 [23%] of the cohort carried at least one ε4 allele) had a higher risk of all-cause mortality compared with non-carriers, with hazard ratios (HR) of 1·16 (95% CI 1·07-1·26) for heterozygotes”

    Humansheterozygotes, compared with non-carriersmedian 15.4 yearsn = 14,091

    The role of dementia in the association between APOE4 and all-cause mortality: pooled analyses of two population-based cohort studies

    The lancet. Healthy longevity

  7. APOE is associated with mortality in humans.

    “empirical findings on the association between APOE and mortality remain inconsistent across studies”

    Review

    Modeling APOE, morbidity, and mortality: a reproducibility challenge for genetic epidemiology

    Frontiers in genetics

p-Tau217

upin humans4mixedin humans1

5 studies
  1. APOE is associated with p-Tau217 in humans (APOE ε4 carriers compared with non-carriers).

    “increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively.”

    HumansAPOE ε4 carriers compared with non-carriersplasma

    Alzheimer’s risk variant linked to steeper blood-marker changes

    Nature communications

  2. APOE is associated with p-Tau217 in humans (APOE4+ participants compared to APOE4- participants).

    “Additionally, p-tau217 was higher among APOE4+ participants compared to APOE4- participants”

    HumansAPOE4+ participants compared to APOE4- participantscerebrospinal fluid

    Protein links to Alzheimer’s markers differ by gene variant

    Neurobiology of disease

  3. APOE is associated with p-Tau217 in humans (apoE-E4 proteotype, adjusting for age and sex).

    “A significant effect of apoE-E4 proteotype on p-tau217 levels, after adjusting for age and sex was identified.”

    HumansapoE-E4 proteotype, adjusting for age and sexplasman = 967

    Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

    NPJ dementia

  4. APOE is associated with p-Tau217 in MCSA and ADNI cohorts.

    “APOE ɛ4 carriership was associated with earlier biomarker progression.”

    Humansin MCSA and ADNI cohorts

    Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition

    Brain : a journal of neurology

  5. APOE is associated with p-Tau217 in humans (dementia-free participants).

    “APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk”

    Humansdementia-free participantsn = 1,356

    Alzheimer disease blood biomarkers and cognition in midlife

    AAIC 2025 abstract

More on p-Tau217

Fractional anisotropy

downin humans2upin humans1mixedin rats1

4 studies
  1. APOE is associated with fractional anisotropy in humans (healthy individuals across the lifespan).

    “We found significant associations between ApoE4 and FA in WM regions associated with neurodegenerative disease even in healthy individuals across the lifespan”

    Humanshealthy individuals across the lifespanwhite matter

    Lifespan reference curves for harmonizing multi-site regional brain white matter metrics from diffusion MRI

    Scientific data

  2. APOE is associated with fractional anisotropy in humans.

    “There was a main effect of APOE, with APOE ɛ4 carriers having higher fractional anisotropy (FA) and lower axial diffusivity (AxD), mean diffusivity (MD), and radial diffusivity (RD) than non-carriers.”

    Humanswhite matter

    Interactive effects of APOE ɛ4 status and vascular burden on white matter microstructural integrity in aging with and without neurocognitive decline

    Journal of Alzheimer's disease : JAD

  3. APOE is associated with fractional anisotropy in rats (humanized APOE4 knock-in rats compared with APOE3 controls).

    “DTI revealed increased FA in the thalamus, brainstem, and white matter tracts, and reduced FA in the sensorimotor cortex.”

    Animalshumanized APOE4 knock-in rats compared with APOE3 controlsthalamus, brainstem, white matter tracts, and sensorimotor cortexfemales

    Multimodal Neuroimaging and Behavioral Characterization of Aged Female APOE4 Knock-In Rats Reveals a Preclinical Alzheimer's Disease Phenotype

    Genes, brain, and behavior

  4. APOE is associated with fractional anisotropy in humans.

    “During ageing, common variants in genes that have been related to increased risk for neuropsychiatric disorders (APOE, HTT, MAPT) were associated in some studies with accelerated local FA decreases over time.”

    Review

    White matter microstructure changes across the lifespan: a meta-analysis of longitudinal diffusion MRI studies

    bioRxiv : the preprint server for biologyPreprint

More on Fractional anisotropy

Cardiovascular disease

upin humans4HR 1.18

4 studies
  1. APOE is associated with cardiovascular disease in people living with HIV on antiretroviral therapy (p = 0.07-0.09).

    “The APOE (rs7412) T allele demonstrated borderline associations with increased CVD risk (p = 0.07-0.09).”

    Humansin people living with HIV on antiretroviral therapyn = 337

    Association Between Patatin-Like Phospholipase Do-Main-Containing Protein-3 Variant and Cardiovascular Disease Risk in People Living With HIV on Antiretroviral Therapy in Taiwan: A Cross-Sectional Study

    Health science reports

  2. APOE is linked with a higher risk of cardiovascular disease in humans (baseline non-statin users) (HR 1.18, 95% CI 1.02-1.38, p = .03).

    “Among non-statin users, APOE4+ had higher incidence of total CVD (hazard ratio [95% confidence interval] = 1.18 [1.02-1.38], p = .03) compared with APOE3 carriers”

    Humansbaseline non-statin usersfemalesn = 6,795

    Relationships Between APOE, Type 2 Diabetes, and Cardiovascular Disease in Postmenopausal Women

    The journals of gerontology. Series A, Biological sciences and medical sciences

  3. APOE raises the risk of cardiovascular disease in humans.

    “Both Alzheimer's disease and cardiovascular disease risks associated with APOE should be addressed for all individuals undergoing testing.”

    Review

    Now is the time: the need to update guidance to expand access to APOE genetic testing

    Frontiers in dementia

  4. APOE raises the risk of cardiovascular disease in humans.

    “APOE4 carriers are predisposed to high cholesterol levels and tend to have an increased risk of cardiovascular disease (CVD).”

    Review

    APOE Lipoprotein Particles: Pathophysiology, Therapy, and the Crosstalk in Alzheimer's Disease and Cardiovascular Disease

    Molecular neurobiology

More on Cardiovascular disease

Hippocampal volume

downin humans3

3 studies
  1. APOE is associated with hippocampal volume in humans (at baseline) (β = -0.27, p = 0.001).

    “The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001)”

    Human trialat baselinehippocampus

    Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. APOE is associated with hippocampal volume in humans (ε4/ε4 homozygosity longitudinally compared to ε3/ε3 and ε3/ε4 carriers).

    “Longitudinally, ε4/ε4 carriers showed greater decline in HpV-Ratio than ε3/ε3 and ε3/ε4 carriers”

    Humansε4/ε4 homozygosity longitudinally compared to ε3/ε3 and ε3/ε4 carriershippocampus4.7 yearsn = 5,774

    Two APOE ε4 copies linked to faster hippocampal shrinkage

    Neuroradiology

  3. APOE is associated with hippocampal volume in humans (APOE e4 presence versus absence) (β range 0.042-0.048 lower versus absence).

    “Significant associations were found between APOE e4 presence and smaller hippocampal volumes (β range 0.042-0.048 lower versus absence)”

    HumansAPOE e4 presence versus absencehippocampusn = 24,912

    Associations and interactions between APOE e4 genotype and lifestyle with brain structural phenotypes

    Brain communications

More on Hippocampal volume

Executive function

mixedin humans1downin humans1

2 studies
  1. APOE is associated with executive function in humans (independent of treatment).

    “APOE4+ carriers showed poorer accuracy on trials requiring response inhibition (F(1, 15935)=12.39, p <.001), and slower RTs across all task trials”

    Human trialindependent of treatmentn = 58

    APOE‐specific Cognitive Effects of Levetiracetam in Mid‐Age Adults

    AAIC 2025 abstract

  2. APOE is associated with executive function in humans (interaction with diet quality (HEI-2020); association present in noncarriers only) (p's = .056-.038).

    “Interaction effects of HEI-2020*APOE-ε4 for EF and WM (p's = .056-.038) were such that diet quality”

    Humansinteraction with diet quality (HEI-2020); association present in noncarriers onlyfemalesn = 102

    APOE-ε4 moderates the association between diet quality and executive function in middle-aged women at increased risk for Alzheimer's disease

    Journal of nutritional science

Amyloid-beta deposition

upin humans2

2 studies
  1. APOE is associated with amyloid-beta deposition in humans (at baseline) (β = 0.48, p = 0.001).

    “greater amyloid deposition (β = 0.48, p = 0.001)”

    Human trialat baselinebrain

    Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. APOE is associated with amyloid-beta deposition in humans (cognitively unimpaired at varying genetic risk for AD) (F(2, 42)=3.26, P=0.048; Ch4, F(2, 42)=3.82, P= 0.03).

    “BFCS amyloid burden was highest among APOE ε4 homozygotes (Ch1-3, F(2, 42)=3.26, P=0.048; Ch4, F(2, 42)=3.82, P= 0.03).”

    Humanscognitively unimpaired at varying genetic risk for ADbrain

    Basal forebrain volume is associated with cortical amyloid burden in cognitively unimpaired older adults at varying genetic risk for Alzheimer's disease

    bioRxiv : the preprint server for biologyPreprint

More on Amyloid-beta deposition

Hippocampal volume

downin humans2

2 studies
  1. APOE is associated with hippocampal volume in humans (baseline) (β = −0.27, p = 0.001).

    “The APOE4 allele was significantly associated with lower hippocampus volume (Table, β = −0.27, p = 0.001) and higher PiB composite score (β = 0.48, p = 0.001).”

    Human trialbaseline2 yearsn = 126

    Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. APOE is associated with hippocampal volume in humans.

    “Total hippocampal volume declined with age, with significant differences by APOE genotype emerging after age 60.”

    Humans

    Hippocampal volumes in UK Biobank are associated with APOE only in older adults

    medRxiv : the preprint server for health sciencesPreprint

Learning and memory response to aerobic exercise

downin humans1

1 study
  1. APOE is associated with learning and memory response to aerobic exercise in humans (Postmenopausal women with breast cancer; group × APOE4 carrier interaction) (Interaction b = -0.544, p = 0.023).

    “APOE4 carriage moderated the effect of aerobic exercise on learning and memory (b = -0.544, p = 0.023).”

    Human trialPostmenopausal women with breast cancer; group × APOE4 carrier interaction6 monthsfemalesn = 116

    APOE Genotype-specific Cognitive Response to Aerobic Exercise in Postmenopausal Women with Breast Cancer

    Biological research for nursing

Mismatch negativity

upin humans1

1 study
  1. APOE is associated with mismatch negativity in humans (subjective cognitive decline) (β = ‒0.449, p = 0.027).

    “APOE ε4 non-carriers showed significantly greater improvement in MMN amplitude (β = ‒0.449, p = 0.027).”

    Human trialsubjective cognitive decline6-monthn = 21

    Baseline predictors of neurophysiological response to combined physical and cognitive training in older adults with subjective cognitive decline

    BMC geriatrics

More on Mismatch negativity

All 303

Funding

157 grants since 2016

National Institute on Aging$213MAlzheimer's AssociationNational Institute of Neurological Disorders and Stroke$11.8M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    APOE is linked with dementia risk and poorer cognition in human studies from independent labs, although other human results show no clear cognitive difference. APOE ε4 is associated with hippocampal atrophy, while independent mouse studies report increased synaptic transmission. Papers and grants name the National Institute on Aging as a funder for 572 findings.

  2. Summary rewritten as its findings changed.

    As it read before

    Human studies associate APOE with lifespan and higher Alzheimer’s disease risk, with cognitive-function associations reproduced by independent labs. Other studies report no effect on Alzheimer’s disease or cognition; independent labs also reproduce increased synaptic transmission and decreased cholesterol in mice. Papers and grants name the National Institute on Aging as a funder on 326 findings.

  3. Summary rewritten as its findings changed.

    As it read before

    Independent labs link APOE to increased Alzheimer’s disease risk in humans, while other reports find no effect or lower risk. Human studies also associate APOE with longevity. The National Institute on Aging is a named funder; one registered trial ended over a year ago without posted results or a citing paper.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that APOE increases Alzheimer’s disease risk and impairs cognition in humans, and induces senescence in human cells. Human results also include unchanged or reduced Alzheimer’s disease risk and improved cognition; one registered trial ended over a year ago without posted results.

  5. Summary rewritten as its findings changed.

    As it read before

    Independent labs reproduce APOE associations with Alzheimer's disease and dementia in human studies. Mortality associations point both ways: lower risk with ε2 versus ε3, but higher risk with two ε4 copies in epilepsy. Both registered trials are sponsored by Lexeo Therapeutics; one ended over a year ago without posted results, and papers declare maker interests.

Latest

Dec 2025: 454Jan 2026: 164Feb 2026: 76Mar 2026: 88Apr 2026: 87May 2026: 79Jun 2026: 94Jul 2026: 76Aug 2026: 74Sep 2026: 84Oct 2026: 91Nov 2026: 481,415 papers in 12 months
Molecular Neurobiology

Mice modeling late-onset Alzheimer’s show memory problems

At 12 months, genetically modified mice of both sexes remembered locations less well than unmodified controls and had modestly fewer projections per length of nerve-cell…At 12 months, genetically modified mice of both sexes remembered locations less well than unmodified controls and had modestly fewer projections per length of nerve-cell branch.

Mouse studyMechanisms
JAMA Neurology

Blood marker and age linked to risk of cognitive impairment

At age 75, estimated five-year risk of mild cognitive impairment was 17% with higher blood marker levels versus 7% with lower levels.At age 75, estimated five-year risk of mild cognitive impairment was 17% with higher blood marker levels versus 7% with lower levels.

Cohort · 1,644 peopleMild cognitive impairment
Wellcome Open Research

Air pollution linked to dementia and heart attacks in Scotland

Above-average exposure was linked to dementia and heart attack, with hazard ratios of 1.48 and 1.79, respectively, compared with lower exposure.Above-average exposure was linked to dementia and heart attack, with hazard ratios of 1.48 and 1.79, respectively, compared with lower exposure.

Cohort · 22,071 peopleAll-cause dementia
Aging Cell

Fat-derived protein worsened signs of vessel aging in mice

In experiments with 24 young male mice over 12 weeks, an antibody against asprosin reduced signs of chemically induced blood vessel aging.In experiments with 24 young male mice over 12 weeks, an antibody against asprosin reduced signs of chemically induced blood vessel aging.

Experiments in miceMechanisms
medRxiv

Blood proteins linked to cognitive response in lifestyle trial

Among 1,158 older adults at risk of dementia, 11 blood proteins were linked to differences in cognitive response to a lifestyle intervention.Among 1,158 older adults at risk of dementia, 11 blood proteins were linked to differences in cognitive response to a lifestyle intervention.

Preprint: trial in 1,158 peopleInterventions

See all 3,893 papers on APOE